Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

Medical Oncology

Volumn 22, Issue 4, 2005, Pages 367-374

  Oral, Ethem Nezih ^a   Aydiner, Adnan ^a   Eralp, Yeşim ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Carboplatin; Chemoradiotherapy; Concomitant boost radiotherapy; Concurrent; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33644834799     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:4:367     Document Type: Article

References (41)

1. Wagner H. Radiation therapy in the management of patients with unresectable stage III A patients and III B non-small cell lung cancer. Semin Oncol 1997;24:423-428.
2. Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol 2000;10(4):289-295.
3. Saunders M, et al. Continuous, hyperfactionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Comittee. Radiother Oncol 1999;52:137-148.
4. Cox J.D, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-1555.
5. Arriagada R, et al. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small-cell lung cancer (NSCLC): late analysis of a French randomized trial. Proc Am Soc Clin Oncol 1997;16:446a.
6. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 84-33 trial. J Natl Cancer Inst 1996;88:1210-1215.
7. Sause WT, et al. Final results of phase III trial in regionally advanced, unresectable non-small-cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
8. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070.
9. Furuse K, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-2699.
10. Curran W, et al. Long term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621a.
11. Mornex F, et al. Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): a French randomized phase III trial of GLOT-GFPC (NPC 95-01 study). Eur J Cancer 2001;37(Suppl 6):28.
12. Zatloukal P, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
13. Gaspar LE. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol 2001;13:110-115.
14. Saunders MI. Programming of radiotherapy in the treatment of non-small cell lung cancer-a way to advance care. Lancet Oncol 2001;2:401-408.
15. Mattson K, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988;24:477-482.
16. Morton RF, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non- small-cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991;115:681-686.
17. Akerley W, et al. Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial by the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 2000;19:1915a.
18. Socinski M, et al. Induction (I) and concurrent (C) carboplatin/ paclitaxel (C/P) with dose-escalated thoracic conformal radiotherapy (TCRT) in stage IIIA/B non-small cell lung cancer (NSCLC): a phase I/II trial. Proc Am Soc Clin Oncol 2000;19:1940a.
19. Nuria V, et al. Radiotherapy (RT) with concurrent paclitaxel plus carboplatin and paclitaxel administered as induction and consolidation chemotherapy (CT) in locally advanced non small cell lung cancer (NSCLC). Phase II trial. Lung Cancer 2003;41:S242.
20. Leong SS, et al. Chemo-radiotherapy for stage III unresectable non-small cell lung cancer - long-term results of a prospective study. Respiratory Medicine 2004;98:1080-1086.
21. Cox JD. Induction chemoterapy for non small cell carcinoma of the lung: limitations and lessons. Int J Radiat Oncol Biol Phys 1991;20:1375-1376.
22. Trott KR, Kummermehr K. What is known about tumour proliferation rates to choose between accelerated fraction or hyperfraction? Radioter Oncol 1984;3:1-10.
23. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146.
24. Schuster-Uitterhoeve ALJ, Hulshof MCCM, Gonzales DG, Koolen M, Sminia P. Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC). Radiother Oncol 1993;28:247-251.
25. Graham MV, Pajak TE, Herskovic AM, Emami B, Perez CA. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys 1995;31:819-825.
26. King SC, et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. Int J Radiat Oncol Biol Phys 1996;36:593-599.
27. Sun LM, et al. Concomitant boost radiation therapy for inoperable non-small cell lung cancer: Preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 2000;47:413-418.
28. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995;22:570-574.
29. Choy H, Safran H. Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995;22:555-557.
30. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
32. Cox JD, et al. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991;20:7-12.
33. Komaki R, et al. Induction cisplatin/vinblastine and irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997;39:537-544.
34. Schaake-Koning C, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Eng J Med 1992;326:524-530.
35. Penland SK, Socinski MA. Management of unresectable stage III non-small-cell lung cancer. The role of combined chemoradiation. Semin Radiat Oncol 2004;14:326-334.
36. Cox JD, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-1555.
37. Saunders MI, et al. Experience with dose escalating using CHARTWEL (continuous, hyperfractionated, accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 1998;78:1323-1328.
38. Fu KK, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
39. Lau DH, et al. Twice weekly paclitaxel and radiation for stage III non-small-cell lung cancer. Semin Oncol 1997; 24(Suppl 12):S12-106-S12-109.
40. Oral EN, et al. Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer 1999;25:191-198.
41. Havemann K, et al. Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small-cell lung cancer. Semin Oncol 1995;22(Suppl 14):19-22.